Avadel Pharma (AVDL) Tops Q2 EPS by 7c, Beats on Revenue

Avadel Pharma (NASDAQ: AVDL) reported Q2 EPS of $0.10, $0.07 better than the analyst estimate of $0.03. Revenue for the quarter came in at $68.13 million versus the consensus estimate of $61.4 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• Active options: NVDA TSLA SPCX AAPL AMZN MU INTC NFLX MSFT PLTR
• Johnson Controls (JCI) 4K contracts of August 120 puts trade, share price down 4%